socalTECH
SEPTEMBER 27, 2012
In a proof that it's not all social media and e-commerce here in Southern California, number two ranking startup in The Wall Street Journal's ranking of the "Top 50 Startups" is none other than wireless hardware provider Xirrus , based in Thousand Oaks. That list included Laguna Hills-based Glaukos at number 7; Donuts Inc. , READ MORE>>.
Xconomy
JULY 26, 2016
Adding to the confusion, the most-recent MoneyTree Report on San Diego venture capital activity shows that Ostendo raised almost $10 million in VC funding during the second quarter. It’s unclear, though, if the $41.8 million disclosed in a July 14 filing includes $27.3M
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
FEBRUARY 5, 2018
When those investors do open their wallets, they’re shunning risky investments in favor of what the Wall Street Journal called “the upper echelon of highly valued startups” such as Airbnb and WeWork. You could make a good case that these investors are taking the “venture” out of “venture capital.”
Xconomy
JULY 17, 2020
In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook.
Xconomy
NOVEMBER 14, 2017
Other investors in the firm include Mayfield , Menlo Ventures , GGV Capital , Inventus Capital , SoftTech VC , Union Grove Venture Partners , and Cross Creek Advisors. That brings the total funding raised by the Redwood City, CA-based company to $160 million.
Xconomy
AUGUST 16, 2016
A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the pharmaceutical industry. Yet despite relative plenty in the bio-venture community, pharma suffers from a shortage of drug candidates.
Xconomy
SEPTEMBER 19, 2016
Charley Grant, writing in The Wall Street Journal , commented that, “Any action to curb price increases on older drugs would hurt manufacturers that rely on them to generate growth.” It has started.”
Expert insights. Personalized for you.
145 
Let's personalize your content